Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Etc.); Or Binds Serum Protein, Plasma Protein (e.g., Tpa, Etc.), Or Fibrin Patents (Class 424/145.1)
-
Publication number: 20140271661Abstract: This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin ? complexed with heparin and/or heparin-like structure (AT?H). These AT?H binding proteins can block the anti-coagulant activity of AT? to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Bayer HealthCare LLCInventors: YE JIN, John E. Murphy, Terry Hermiston, Timothy Myler, Frank Dittmer, Michael Strerath, Uwe Gritzan
-
Publication number: 20140271660Abstract: This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin ? complexed with heparin and/or heparin-like structure (AT?H). These AT?H binding proteins can block the anti-coagulant activity of AT? to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: BAYER HEALTHCARE LLCInventors: YE JIN, JOHN E. MURPHY, TERRY HERMISTON, TIMOTHY MYLES, FRANK DITTMER, MICHAEL STRERATH, UWE GRITZAN
-
Publication number: 20140271646Abstract: Monoclonal antibodies (mAbs), antigen binding fragments and engineered antibody domains (eAds) that specifically bind IGF-II are disclosed herein. In some embodiments, these mAbs and eAds are included in a bispecific mAb. In some embodiments, the bispecific antibody specifically binds two different epitopes of IGF-II. Methods of using these mAbs, antigen binding fragments, and eAds, bispecific antibodies, and nucleic acids encoding these mAbs, antigen binding fragments, and eAds, bispecific antibodies are also disclosed.Type: ApplicationFiled: October 16, 2012Publication date: September 18, 2014Inventors: Dimiter S. Dimitrov, Weizao Chen, Yang Feng
-
Patent number: 8834879Abstract: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.Type: GrantFiled: April 3, 2013Date of Patent: September 16, 2014Assignee: ZymoGenetics, Inc.Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
-
Patent number: 8834883Abstract: Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.Type: GrantFiled: June 14, 2011Date of Patent: September 16, 2014Assignee: Vaccinex, Inc.Inventors: Leslie A. Croy, Mark J. Paris, Ernest S. Smith
-
Publication number: 20140255397Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: May 20, 2014Publication date: September 11, 2014Applicants: Ludwig Institute for Cancer Research, The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Patent number: 8828390Abstract: The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus.Type: GrantFiled: July 8, 2011Date of Patent: September 9, 2014Assignees: Universitat Zurich, Universite de GeneveInventors: Pedro L. Herrera, Martin E. Schwab, Claire Bonal, Patrice Lalive D'epinay, Caroline Pot Kreis
-
Patent number: 8828386Abstract: A method lessening intraventricular hemorrhage in the fetus of a gravid human patient is provided where the patient is administered a therapeutically effective amount of digoxin antibody.Type: GrantFiled: February 13, 2012Date of Patent: September 9, 2014Assignees: Glenveigh Pharmaceuticals, LLC, CDA Royalty Investors, LLCInventor: Charles David Adair
-
Publication number: 20140248279Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.Type: ApplicationFiled: May 12, 2014Publication date: September 4, 2014Applicants: Merck Sharp & Dohme Corp., The Government of the United States of America as represented by the Secretary of the Department ofInventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
-
Patent number: 8822645Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: July 8, 2009Date of Patent: September 2, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Jijie Gu, Peter C. Isakson
-
Patent number: 8822423Abstract: We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.Type: GrantFiled: May 17, 2012Date of Patent: September 2, 2014Assignee: Janssen Biotech, Inc.Inventors: Daphne Ann Salick Ryan, John Kehoe, John Wheeler, Chunlin Yang, Abla Creasey
-
Publication number: 20140242165Abstract: A biocompatible carrier for delivery of a therapeutic substance or an active agent is disclosed. The carrier contains a bioadhesive material allowing for increased residence time of the active agent at the treatment site.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventor: Wouter E. Roorda
-
Publication number: 20140234303Abstract: The present invention is directed to a method for treating an inflammatory neurodegenerative condition of the CNS in a subject comprising administering to said subject a G-CSF or G-CSFR inhibiting agent selected from the group consisting of an antibody specific for G-CSF, a soluble G-CSFR or a G-CSF-binding portion thereof and a 20 to 30 nucleotide sense or antisense molecule targeted to a nucleic acid molecule encoding G-CSF.Type: ApplicationFiled: March 24, 2014Publication date: August 21, 2014Applicant: CSL LIMITEDInventors: Brent Steven McKenzie, Peter Frederick CURWEN, Eugene MARASKOVSKY
-
Patent number: 8802102Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: January 3, 2014Date of Patent: August 12, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8802103Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.Type: GrantFiled: May 15, 2008Date of Patent: August 12, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
-
Patent number: 8802096Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.Type: GrantFiled: November 26, 2010Date of Patent: August 12, 2014Assignee: Inflarx GmbHInventors: Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen
-
Patent number: 8802100Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: November 27, 2013Date of Patent: August 12, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8802097Abstract: The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: GrantFiled: July 13, 2012Date of Patent: August 12, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Fumiko Takada Axelrod, Timothy Charles Hoey, Cecile Chartier-Courtaud
-
Patent number: 8802101Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: November 27, 2013Date of Patent: August 12, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8795656Abstract: The use of an IL-3 inhibitor for prophylactic treatment of rheumatoid arthritis, for treatment of rheumatoid arthritis in an early stage, during early phases of exacerbation, or as maintenance therapy to prevent disease flares or disease progression in a subject is described.Type: GrantFiled: December 4, 2009Date of Patent: August 5, 2014Assignee: Klinikum der Universitat RegensburgInventors: Matthias Mack, Hilke Brühl
-
Patent number: 8795663Abstract: The invention provides isolated soluble endoglin polypeptides, nucleic acids encoding soluble endoglin polypeptides, antibodies that specifically bind soluble endoglin polypeptides, and kits containing these materials. The invention also provides methods for treating or decreasing the likelihood of developing a soluble endoglin-mediated disorder in a subject requiring the administration of an agent capable of reducing the expression or biological activity of a soluble endoglin polypeptide and methods for treating or decreasing the likelihood of developing a soluble endoglin-preventive disorder in a subject requiring the administration of a soluble endoglin polypeptide or a nucleic acid encoding the soluble endoglin polypeptide. The invention further provides methods for the diagnosis of a soluble endoglin-mediated disorder or a soluble endoglin-preventive disorder and methods for identifying a compound to treat a soluble endoglin-mediated or a soluble endoglin-preventive disorder.Type: GrantFiled: January 11, 2011Date of Patent: August 5, 2014Assignee: Beth Israel Deaconess Medical Center, Inc.Inventor: Mourad Toporsian
-
Patent number: 8795665Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to human BMP-6, compositions comprising such antibodies, or antigen-binding fragments thereof, and methods of using the same for treatment of anemia of chronic disease.Type: GrantFiled: December 5, 2013Date of Patent: August 5, 2014Assignee: Eli Lilly and CompanyInventors: Neungseon Seo, Stephanie Marie Eaton Truhlar
-
Patent number: 8795670Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: November 27, 2013Date of Patent: August 5, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8795666Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: GrantFiled: February 7, 2013Date of Patent: August 5, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Madaline Chirica, Robert A. Kastelein, Kevin Moore, Christi L. Parham
-
Publication number: 20140212424Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.Type: ApplicationFiled: February 28, 2014Publication date: July 31, 2014Applicant: AbbVie Biotherapeutics Inc.Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
-
Publication number: 20140212355Abstract: It is provided herein methods, devices, and compositions for trans-arterial local delivery of therapeutic agent for the treatment of liver cancers.Type: ApplicationFiled: January 28, 2013Publication date: July 31, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Mikael TROLLSAS, Syed Hossainy, John Stankus, Paul Consigny
-
Patent number: 8791242Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.Type: GrantFiled: November 11, 2011Date of Patent: July 29, 2014Assignee: Intervet Inc.Inventors: Jeanine D. Mattson, Daniel M. Gorman, Rene de Waal Malefyt, Mohamad A. Morsey
-
Patent number: 8790652Abstract: Provided herein are methods for inhibiting tumor angiogenesis in a cancer patient, the method comprising administering to the subject an effective amount of a first isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) and an effective amount of a second isolated binding molecule which specifically binds to VEGF.Type: GrantFiled: December 6, 2012Date of Patent: July 29, 2014Assignee: Vaccinex, Inc.Inventors: John R. Basile, Elizabeth E. Evans, Ernest S. Smith
-
Patent number: 8790651Abstract: An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.Type: GrantFiled: June 28, 2012Date of Patent: July 29, 2014Assignee: Zoetis LLCInventors: Gary F. Bammert, Steven A. Dunham
-
Patent number: 8790643Abstract: Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2R?; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.Type: GrantFiled: November 8, 2010Date of Patent: July 29, 2014Assignee: ZymoGenetics, Inc.Inventors: Pallavur V. Sivakumar, Stephen R. Jaspers
-
Patent number: 8790642Abstract: The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses.Type: GrantFiled: August 26, 2009Date of Patent: July 29, 2014Assignee: Genentech, Inc.Inventors: Yongmei Chen, Yan (Helen) Hu, Wenjun Ouyang, Scott Stawicki, Yan Wu
-
Publication number: 20140205611Abstract: Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.Type: ApplicationFiled: January 28, 2014Publication date: July 24, 2014Applicants: Boehringer Ingelheim International GmbH, Evec Inc.Inventors: Kenzo Takada, Kantou Nakajima, John Park, Barbara Kistler
-
Patent number: 8784818Abstract: The present invention provides anti-VEGFR-3 monoclonal antibodies, pharmaceutical compositions containing said antibodies and uses of said antibodies in the treatment of disease.Type: GrantFiled: May 7, 2013Date of Patent: July 22, 2014Assignee: ImClone LLCInventors: Bronislaw Pytowski, Krishnadatt Persaud, Nathalie Zayek
-
Patent number: 8784809Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: January 24, 2013Date of Patent: July 22, 2014Assignee: Human Genome Sciences, Inc.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Patent number: 8785605Abstract: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).Type: GrantFiled: March 30, 2011Date of Patent: July 22, 2014Assignee: Janssen Biotech, Inc.Inventors: Juan Carlos Almagro, Patrick Branigan, Colleen Kane, William Strohl, Susann Taudte, Mark Tornetta, John Wheeler
-
Patent number: 8784817Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.Type: GrantFiled: February 14, 2013Date of Patent: July 22, 2014Assignee: XBiotech, Inc.Inventor: John Simard
-
Patent number: 8784816Abstract: The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII.Type: GrantFiled: October 23, 2012Date of Patent: July 22, 2014Assignee: Life Sciences Research Partners VZWInventors: Marc G. Jacquemin, Jean-Marie R. Saint-Remy
-
Publication number: 20140199322Abstract: The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.Type: ApplicationFiled: March 20, 2014Publication date: July 17, 2014Applicant: DePuy Synthes Products, LLCInventors: Mohamed Attawia, Thomas M. DiMauro, Hassan Serhan, Sudhakar Kadiyala, David Urbahns, Scott Bruder
-
Publication number: 20140199361Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.Type: ApplicationFiled: July 20, 2012Publication date: July 17, 2014Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
-
Publication number: 20140199299Abstract: This invention relates generally to compositions that contain multiple modulating agents, e.g., multiple modulating agents that target CD3 on T cells and neutralize one or more biological activities of interleukin-6 (IL-6), such as CD3 modulators including anti-CD3 antibodies and anti-IL-6 antagonists including anti-IL-6 antibodies, anti-IL-6R antagonists including anti-IL-6R antibodies, and/or anti-IL-6/IL-6R complex antagonists including anti-IL-6/IL-6R binding antibodies, and methods of using these compositions in the treatment, amelioration and/or prevention of relapse of an autoimmune disease.Type: ApplicationFiled: March 20, 2014Publication date: July 17, 2014Inventors: Yann Dean, Fabien Depis
-
Publication number: 20140199399Abstract: The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-? antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-? antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.Type: ApplicationFiled: December 23, 2013Publication date: July 17, 2014Applicants: The General Hospital Corporation, Genzyme CorporationInventors: James B. STREISAND, Jesse D. ROBERTS, JR.
-
Patent number: 8778344Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: January 26, 2012Date of Patent: July 15, 2014Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond
-
Patent number: 8779103Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.Type: GrantFiled: March 24, 2010Date of Patent: July 15, 2014Assignee: Glaxo Group LimitedInventors: Christopher Herring, Lucy J. Holt, Laurent S. Jespers, Sebastian Mayer, Malgorzata Pupecka-Swider
-
Patent number: 8771697Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: GrantFiled: June 8, 2012Date of Patent: July 8, 2014Assignee: Novimmune SAInventors: Krzysztof Masternak, Olivier Leger
-
Patent number: 8771692Abstract: The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.Type: GrantFiled: July 2, 2010Date of Patent: July 8, 2014Assignee: FibroGen, Inc.Inventors: Enrique Brandan, Roel Goldschmeding, Noelynn A. Oliver
-
Patent number: 8771686Abstract: The present inventors focused on the fact that inflammation at the subretinal macular area enhances choroidal neovascularization, and developed pharmaceutical agents that suppress initiation or advancement of neovascularization by angiogenic factors such as VEGF. More specifically, the present inventors revealed that administering anti-IL-6 receptor monoclonal antibodies to mice treated with laser photocoagulation inhibits the development of choroidal neovascularization.Type: GrantFiled: January 26, 2007Date of Patent: July 8, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Susumu Ishida
-
Publication number: 20140186295Abstract: Described herein are methods for the treatment of cancer (e.g. melanoma, lung cancer, or other cancers). The methods involve administrating to a subject in need thereof an agonist of the IL-9 receptor (e.g. IL-9), e.g. an agent that binds and activates the IL-9 receptor, or an agent that increases IL-9 expression in the subject (e.g. administration of TH9 cells that express IL-9, or administration of an inhibitor of ROR).Type: ApplicationFiled: March 22, 2012Publication date: July 3, 2014Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Thomas S. Kupper, Rahul Purwar
-
Publication number: 20140186364Abstract: The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells.Type: ApplicationFiled: December 19, 2013Publication date: July 3, 2014Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE CLAUDE BERNARD LYON 1, ECOLE NORMALE SUPERIEURE DE LYON, CENTRE LEON BERARDInventors: Patrick Etienne-Roger MEHLEN, Servane Marie-Séverine Tauszig-Delamasure, Céline Jacqueline-Andrée Delloye, Jimena Bouzas-Rodriguez
-
Patent number: 8765131Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: February 5, 2013Date of Patent: July 1, 2014Assignee: Genentech, Inc.Inventors: Michael Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8765918Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: March 23, 2012Date of Patent: July 1, 2014Assignee: Abbott GmbH & Co., KGInventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou